RUXIENCE Q Code: Q5119

Drug & Product Overview

HCPCS Descriptor Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg

HCPCS Added Date July 1, 2020

Manufacturer Pfizer

Route of Administration Intravenous

Generic Status Single-Source; Branded

Dosage Type Single-Dose

Dosage Form Injection, Solution

About RUXIENCE

Ruxience is a medication aligned to the HCPCS Q Code: Q5119 for billing, pricing, and reimbursement purposes in the United States. Classified under Oncology, it is administered via the intravenous route and manufactured by Pfizer.

According to CMS Drug Use Information: Rituximab is used to treat certain types of cancer (such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia). It works by slowing or stopping the growth of cancer cells. Some brands of rituximab are also used to treat rheumatoid arthritis and can decrease joint pain and swelling. This drug is also used to treat certain types of blood vessel disease (such as granulomatosis with polyangiitis, microscopic polyangiitis) and can decrease the swelling of the blood vessels. Rituximab is also used to treat a certain skin condition (pemphigus vulgaris). It helps to reduce the number of skin lesions. This monograph is about the following rituximab products: rituximab, rituximab-abbs, rituximab-arrx, and rituximab-pvvr.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
00069-0238-01	Ruxience	Pfizer Laboratories Div Pfizer Inc	10	100 MG / 10 ML
00069-0249-01	Ruxience	Pfizer Laboratories Div Pfizer Inc	50	500 MG / 50 ML

Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

RUXIENCE Pricing & Reimbursement

Q5119 Private Payer Reimbursement

$17.45 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →

Historical Graphing and Billing Calculator

per HCPCS unit

As of Q3 2026

Rituximab Biosimilar Information:

RUXIENCE Approval Date: July 23, 2019

Product Name	HCPCS Code	Active Ingredient	BLA Type
Rituxan	J9312	Rituximab	351(a) Originator Product
Truxima	Q5115	Rituximab	351(k) Interchangeable
Ruxience	Q5119	Rituximab	351(k) Biosimilar
Riabni	Q5123	Rituximab	351(k) Biosimilar
Zimrixby	N/A	Rituximab	351(k) Biosimilar

RUXIENCE Claims Performance

Claims from Jan 2026 – Aug 2026

Claim Denial Rate 14.77%

Avg. Days to File 14.2days

Avg. Days to Pay 26.7days

Real-world claims performance from FocalPoint, OnPoint Oncology's reimbursement analytics platform, with claims data accrued at the clearing house level.

Explore Q5119 claims analytics on FocalPoint →

RUXIENCE CPT Administration Codes

CPT Code	Description
96413	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
96415	Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)

JW / JZ modifiers apply

CMS has identified Ruxience (Q5119) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. Wastage billing guide →

RUXIENCE Medically Unlikely Edits (MUE)

The most billing units of Q5119 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 10 mg.

Practitioner Office & Hospital Outpatient

150 units / day

= 1,500 mg per day

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

RUXIENCE Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Chronic Lymphocytic Leukemia (CLL) Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) Non-Hodgkin's Lymphoma (NHL) Pemphigus Vulgaris (PV) Rheumatoid Arthritis (RA)

Drug Class

CD20-directed Antibody Interactions [MoA]CD20-directed Cytolytic Antibody [EPC]

Frequently Asked Questions

Is there an available Ruxience billing and coding guide?

Billing and coding information for RUXIENCE can be found through Pfizer. Visit Here →

Are there any available Ruxience patient assistance programs?

RUXIENCE patient assistance information can be found through Pfizer. Visit Here →

Where can I find Ruxience prescribing information?

RUXIENCE prescribing information can be found at the link below: Visit Here →

Where can I find Ruxience side effect information?

Information regarding RUXIENCE's side effects can be found at MedlinePlus Visit Here →

Does billing RUXIENCE require JZ/JW wastage modifiers?

CMS has identified RUXIENCE(Q5119) as a HCPCS code with single-dose containers. Therefore, the JW/JZ wastage modifiers could be required for billing purposes. See CMS guidelines on use of the JZ and JW wastage modifiers below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.